{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "https://eldaddp.azurewebsites.net/answeredquestions.text?ddpModified.=2023-05-11T19%3A56%3A26.317Z&dateTabled=2023-05-11", "definition" : "https://eldaddp.azurewebsites.net/meta/answeredquestions.text?ddpModified.=2023-05-11T19%3A56%3A26.317Z&dateTabled=2023-05-11", "extendedMetadataVersion" : "https://eldaddp.azurewebsites.net/answeredquestions.text?ddpModified.=2023-05-11T19%3A56%3A26.317Z&dateTabled=2023-05-11&_metadata=all", "first" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&ddpModified.=2023-05-11T19%3A56%3A26.317Z&dateTabled=2023-05-11", "hasPart" : "https://eldaddp.azurewebsites.net/answeredquestions.text?ddpModified.=2023-05-11T19%3A56%3A26.317Z&dateTabled=2023-05-11", "isPartOf" : "https://eldaddp.azurewebsites.net/answeredquestions.text?ddpModified.=2023-05-11T19%3A56%3A26.317Z&dateTabled=2023-05-11", "items" : [{"_about" : "http://data.parliament.uk/resources/1627182", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1627182/answer", "answerText" : {"_value" : "<p>The Medicines and Healthcare products Regulatory Agency (MHRA) has made no evaluation of Evusheld 2. Should such an application be received, the MHRA will review this for quality, safety and effectiveness and the overall benefit risk. The MHRA, together with independent advisory groups, continues to review the emerging body of evidence regarding potential medicines for the prevention or treatment of COVID-19.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4948", "label" : {"_value" : "Biography information for Lord Markham"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord Markham"}
        , "dateOfAnswer" : {"_value" : "2023-05-26", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2023-05-26T13:44:55.99Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2023-05-11", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Sipavibart"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask His Majesty's Government what assessment they have made of the effectiveness of Evusheld 2 in protecting clinically extremely vulnerable and immunocompromised people against COVID-19; and whether there are plans for it to be made available on the NHS.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4308", "label" : {"_value" : "Biography information for The Lord Bishop of St Albans"}
      }
      , "tablingMemberPrinted" : [{"_value" : "The Lord Bishop of St Albans"}
      ], "uin" : "HL7791"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 1, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}